

Evidence for your approach


ASSIST Registry results

How you perform thrombectomy is a personalized decision you make based on your team and ultimately the patients you treat. We at Stryker set out to compare the clinical results of different thrombectomy techniques by creating the ASSIST Registry.

This core lab adjudicated study captured real-world data from 1,500 subjects across 71 sites worldwide using Stryker’s Total Stroke portfolio. Below is the data from the first 1,300 subjects.

Excellent real-world results, no matter the technique

Stryker’s Total Stroke portfolio can help you achieve excellent results, no matter your technique. We are committed to investing in clinically proven solutions for you and your patients. We’re with you all the way.



	SR + BGC	Combination	Aspiration*
90D mRS 0-2	58%	52%	59%
1st-pass eTICI			
2c+	48%	46%	39%
2b+	71%	73%	63%
Final eTICI			
2c+	71%	66%	68%
2b+	97%	95%	97%
Mean # passes	1.6	1.6	1.8
Median time to final reperfusion: (minutes)	34	36	32

N=79 subjects excluded due to inadequate imaging or due to order & sequence of treatment being impacted by angioplasty

Across all techniques

55%

90D mRS 0-2


44%

TICI 2c+ on first pass

1.6

Mean # passes

*Approximately 9% of the first 1,300 subjects treated with AXS Vecta aspiration/intermediate catheter. Future data will include N=200 additional subjects treated with 0.071in or 0.074in catheters



ASSIST Study

- Prospective, consecutive enrollment registry
- All-comer patient population with anterior LVO
- Core lab adjudicated - 100% procedure data fully verified
- 71 sites in 11 countries
- Stryker's Total Stroke products used on the 1st pass
- Three technique arms SR+BGC(N=250), combination(N=697), aspiration(N=353)

	SR + BGC	Combination	Aspiration*
Pre-stroke mRS			
0-1	82%	81%	86%
0-2	90%	88%	93%
NIHSS at presentation			
	15	14	14
Occlusion location			
Distal ICA	15%	16%	22%
M1	58%	53%	56%
M2	27%	32%	22%
Tandem occlusion			
	11%	15%	14%
Results			
90-Day mRS			
0-1	47%	39%	48%
0-2	58%	52%	59%
sICH	2.4%	1.9%	2.0%
Embolization to new territory			
	0.4%	0.9%	0.0%
Stroke related mortality			
	8.0%	8.9%	5.7%

This document is intended solely for the use of healthcare professionals.

A physician must always rely on his or her own professional clinical judgment when deciding whether to use a particular product when treating a particular patient. Stryker does not dispense medical advice and recommends that physicians be trained in the use of any particular product before using it in a procedure. The information presented is intended to demonstrate the breadth of Stryker product offerings. A physician must always refer to the package insert, product label and/or instructions for use before using any Stryker product. Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your Stryker representative if you have questions about the availability of Stryker products in your area.

Stryker or its affiliated entities own, use, or have applied for the following trademarks or service marks: Stryker, Total Stroke. All other trademarks are trademarks of their respective owners or holders.

The absence of a product, feature, or service name, or logo from this list does not constitute a waiver of Stryker's trademark or other intellectual property rights concerning that name or logo.

NZ New Zealand Sponsor Address
Stryker New Zealand Ltd
PO Box 17136
Greenlane 1546
Auckland
New Zealand

AUS Australian Sponsor Address
Stryker Australia Pty Ltd
8 Herbert Street
St Leonards, NSW 2065
Australia

Stryker Neurovascular
47900 Bayside Parkway
Fremont, CA 94538
stryker.com
Date of Release: FEB/2022
EX_EN_GL